Skip to main content

Table 2 Proportions of underlying biomedical and demographic characteristics and unadjusted hazard ratios among cART recipients attending two HIV clinics in Gaborone, Botswana. Status variable: Diabetes mellitus-related comorbidities (DRCs, N = 531)

From: Relationship between combination antiretroviral therapy regimens and diabetes mellitus-related comorbidities among HIV patients in Gaborone Botswana

Covariates

Proportion Number (%)

Unadjusted

HR

95%CI

P value

Male

163 (30.7)

0.58

0.38–0.89

0.012

Age ± SE

41.39 ± 0.38

1.03

1.01–1.05

0.006

≤35 years old

132 (24.9)

0.40

0.20–0.80

0.01

CD4–1 ≤ 200 cells/mm3

124 (23.4)

1.6

1.03–2.6

0.036

CD4–1 ≥ 350 cells/mm3

24 (4.5)

0.99

0.31–3.16

0–90

CD4–2 ≤ 200 cells/mm3

34 (6.4)

0.94

0.38–2.32

0.89

CD4–2 ≥ 350 cells/mm3

420 (79.1)

1,16

0.67–2.04

0.58

PMH Clinic

314 (50.1)

6.41

3.55–11.56

0.001

Adherence

No

31 (5.8)

1

Yes

478 (90.0)

4.53

1.42–14.47

0.01

Unknown

22 (4.1)

1.14

0.41–3.12

0.79

1Switched cART Line

Did not switch

235 (44.3)

1

From cART line1 to line 2

281 (52.9)

0.75

0.49–1.15

0.18

Unknown

15 (2.8)

1.28

0.46–3.58

0.63

BMI at cART

Normal weight

337 (63.5)

1

Underweight

80 (15.1)

0.88

0.46–1.69

0.71

Overweight

114 (21.4)

1.63

1.02–2.61

0.043

  1. HR = Hazard ratio, CI = confidence interval, 1Switched cART regimens = switched from the initial cART line to another line, Unknown = whether the patient switched regimen or not is unclear, BMI at cART = BMI at initiation on cART, CD4–1 cells/mm3 = CD4 count at initiation on cART, CD4–2 cells/mm3 = CD4 count after initiation on cART